Background: Alzheimer's disease is the most common form of dementia and is a major contributor to morbidity and mortality in older Australians.
Objective: The aim of this article is to provide an overview of available pharmacological therapies for the symptomatic treatment of Alzheimer's disease.
Discussion: Acetylcholinesterase inhibitors (AChEIs) or memantine may be trialled in people with Alzheimer's disease to delay symptoms of cognitive and functional decline. The choice of pharmacological agent is based on the stage of Alzheimer's disease, tolerability, adverse effect profile, ease of use and cost. People should be monitored for efficacy, side effects and possible treatment discontinuation. Strategies should be used to optimise medication management and adherence. Evidence for other pharmacological therapies is mixed or lacking. Behavioural and psychological symptoms of dementia (BPSD) are common in people with Alzheimer's disease and may respond to symptomatic pharmacological and non-pharmacological treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.31128/AJGP-05-18-4586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exosomes and non-coding RNAs: bridging the gap in Alzheimer's pathogenesis and therapeutics.
Metab Brain Dis
January 2025
Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530000, China.
Alzheimer's disease (AD) is a neurodegenerative disease that primarily affects the elderly population and is the leading cause of dementia. Meanwhile, the vascular hypothesis suggests that vascular damage occurs in the early stages of the disease, leading to neurodegeneration and hindered waste clearance, which in turn triggers a series of events including the accumulation of amyloid plaques and Tau protein tangles. Non-coding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), have been found to be involved in the regulation of AD.
View Article and Find Full Text PDFMapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis.
Eur J Nucl Med Mol Imaging
January 2025
Huashan Hospital and Human Phenome Institute, Fudan University, 220 Handan Road, Shanghai, 200433, China.
Objective: This study aims to conduct a bibliometric analysis to explore research trends, collaboration patterns, and emerging themes in the PET/MR field based on published literature from 2010 to 2024.
Methods: A detailed literature search was performed using the Web of Science Core Collection (WoSCC) database with keywords related to PET/MR. A total of 4,349 publications were retrieved and analyzed using various bibliometric tools, including VOSviewer and CiteSpace.
Exploring SERPINA3 as a neuroinflammatory modulator in Alzheimer's disease with sex and regional brain variations.
Metab Brain Dis
January 2025
Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Catania, Italy.
SERPINA3, a serine protease inhibitor, is strongly associated with neuroinflammation, a typical condition of AD. Its expression is linked to microglial and astrocytic markers, suggesting it plays a significant role in modulating neuroinflammatory responses. In this study, we examined the SERPINA3 expression levels, along with CHI3L1, in various brain regions of AD patients and non-demented healthy controls (NDHC).
View Article and Find Full Text PDFThe link between eye movements and cognitive function in mild to moderate Alzheimer's disease.
Exp Brain Res
January 2025
Department of Neurology and Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, No. 1055, Sanxiang Road, Suzhou, 215004, Jiangsu Province, People's Republic of China.
This study investigated the relationship between eye movement parameters and cognitive function in patients with mild to moderate Alzheimer's disease (AD). A total of 80 patients with AD (mild and moderate) and 34 normal controls (NC) participated. Neuropsychological assessments were conducted using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), while eye movements were recorded using eye-tracking technology.
View Article and Find Full Text PDFAlzheimer's disease and diabetes-associated cognitive dysfunction: the microglia link?
Metab Brain Dis
January 2025
Department of Pharmacy, the Second Affiliated Hospital of Shaoyang University, Shaoyang, Hunan, China.
Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ) plaques and the aggregation of tau protein, resulting in intense memory loss and dementia. Diabetes-associated cognitive dysfunction (DACD) is a complication of diabetes mellitus, which is associated with decreased cognitive function and impaired memory. A growing body of literature emphasize the involvement of microglia in AD and DACD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!